Stockscreener 앱 받기
5.22
0.76%
-0.04
시간 외 거래:
5.08
-0.14
-2.68%
Minerva Neurosciences Inc 주식(NERV)의 최신 뉴스
Minerva Neurosciences Inc (NERV) Q1 2026 Earnings: Wider Loss Highlights Ongoing Pre-Revenue Development StageDownward Estimate Revision - Newser
Minerva Neurosciences Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Faces Challenges - Newser
All you need to know about Minerva Neurosciences (NERV) rating upgrade to buy - MSN
Minerva Neurosciences Q1 2026 Earnings: EPS Misses Street Estimates, Stock Gains on Pipeline OptimismPost-Earnings Drift - Newser
NERV Should I Buy - Intellectia AI
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy - Yahoo Finance
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
Minerva CEO to join Jefferies 2026 healthcare fireside chat June 4 - Stock Titan
Minerva Neurosciences (NERV) Slides -5.22% as Selling Pressure Mounts 2026-05-15Popular Market Picks - Newser
Janus Henderson (NERV) reports 4.3M shares, 9.9% stake disclosed - Stock Titan
Balyasny group (NASDAQ: NERV) discloses a 9.99% stake of 4.32M shares - Stock Titan
TradingKey - TradingKey
Minerva Neurosciences (NERV) Slips -0.90%, Testing $5.22 Support 2026-05-14Social Momentum Signals - newser.com
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Raises Target Price to $7 - Moomoo
8-K: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updatesmoomoo - Moomoo
Minerva Neurosciences, Inc. 1Q 2026: Revenue $0 Net loss $(125.4M), EPS $(2.86) — 10-Q Summary - TradingView
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Minerva Neurosciences (NERV) posts large Q1 2026 non-cash loss but keeps cash runway - Stock Titan
Minerva Neurosciences Posts 1Q $109.4M Non-Cash Expense For Change in Fair Value of Warrant Liability, Losses Recognized Upon Exercise of Warrants - Moomoo
Phase 3 roluperidone trial and larger Q1 loss at Minerva (NERV) - Stock Titan
Minerva Neurosciences: Q1 Earnings Snapshot - marketscreener.com
No approved drug targets these schizophrenia symptoms; Phase 3 starts - Stock Titan
Press Release: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates - Moomoo
Minerva Neurosciences starts Phase 3 trial for roluperidone to treat negative schizophrenia symptoms - Pluang
Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update - MarketBeat
Minerva launched with new outperform at Citizens on schizophrenia candidate - MSN
Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69 - MSN
Minerva Neurosciences | 8-K: Current report - Moomoo
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Officer liability and pay votes at Minerva Neurosciences (NASDAQ: NERV) 2026 meeting - Stock Titan
NERV (Minerva Neurosciences Inc) posts wider than expected Q4 2025 loss yet shares rise 5.28 percent on bullish investor sentiment.ADR - UBND thành phố Hải Phòng
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - Stock Titan
Minerva Neurosciences (NERV) officer James O’Connor files Form 3 - Stock Titan
NERV Initiates Coverage On Citizens -- Rating Set to Market Outp - GuruFocus
Minerva stock wins New Outperform at Citizens (NERV:NASDAQ) - Seeking Alpha
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens Jmp - MarketBeat
Citizens initiates Minerva Neurosciences stock at outperform, $14 target By Investing.com - Investing.com South Africa
Citizens initiates Minerva Neurosciences stock at outperform, $14 target - Investing.com
Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest - MarketBeat
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences - Yahoo Finance
Retail Surge: Is Minerva Neurosciences Inc stock technically oversold2026 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Minerva Neurosciences (NASDAQ: NERV) proxy: charter amendments, say‑on‑pay vote - Stock Titan
Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below Fifty Day Moving AverageShould You Sell? - MarketBeat
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline - The Globe and Mail
Minerva Neurosciences, Inc. Files Form 8-K with SEC – Company Information and Key Details (April 6, 2026) 14 - Minichart
0.98%
0.12%
자본화:
|
볼륨(24시간):